Drug Safety

, Volume 30, Issue 7, pp 555–567

Negative Effects of Antiepileptic Drugs on Mood in Patients with Epilepsy

Review Article

Abstract

With the introduction of several new antiepileptic drugs into clinical practice, renewed attention has been focussed on treatment-emergent adverse effects, including mood disorders. There are several possible causes of psychiatric disorders in patients with epilepsy, including antiepileptic drugs, and it is often difficult to determine whether psychopathological manifestations, especially depressive symptoms, are due to drug therapy or to multiple other factors. Assessment of the negative effects of antiepileptic drugs on mood should always consider all potential factors. Case series, audits and open observational studies can identify psychopathological features, case-control studies are useful for identifying the endophenotypes of patients at risk of adverse effects on mood, and controlled clinical trials give good estimates of incidence of such effects, adjusted for the spontaneous occurrence of symptoms.

The barbiturates, vigabatrin and topiramate show greater associations with the occurrence of depressive symptoms than other antiepileptic drugs, presenting in up to 10% of all patients, but even more so in susceptible patients. Data on zonisamide are scarce but it seems that mood disorders may occur in approximately 7% of patients who are receiving high dosages of this drug. In most cases, the use of monotherapy, with slow titration schedules, can significantly reduce the incidence of mood disorders. Tiagabine, levetiracetam and felbamate present an intermediate risk, with prevalence of depression of about 4% or lower. Phenytoin, ethosuximide, carbamazepine, oxcarbazepine, gabapentin, sodium valproate, pregabalin and lamotrigine are all associated with low risks for depression (<1%), and several of these antiepileptic drugs seem to have a positive effect on mood. Antiepileptic drugs can negatively affect mood and behaviour by different mechanisms: potentiation of GABA neurotransmission, folate deficiency, pharmacodynamic interactions with other antiepileptic drugs in polytherapy regimens, forced normalisation.

Individuals with a personal or family history of depression should be carefully followed after initiation of therapy with a new antiepileptic drug, especially if structural brain abnormalities such as hippocampal sclerosis are present.

References

  1. 1.
    Turner WA. Epilepsy: a study of the idiopathic disease. New York (NY): MacMillian, 1907: 230Google Scholar
  2. 2.
    Gaitatzis A, Trimble MR, Sander JW. The psychiatric comorbidity of epilepsy. Acta Neurol Scand 2004; 110(4): 207–20PubMedCrossRefGoogle Scholar
  3. 3.
    Mattson RH. Cognitive, affective, and behavioural side effects in adults secondary to antiepileptic drug use. Rev Neurol Dis 2004; 1 Suppl. 1: S10–7PubMedGoogle Scholar
  4. 4.
    Rodin EA, Katz M, Lennox K. Differences between patients with temporal lobe seizures and those with other forms of epileptic attacks. Epilepsia 1976; 17(3): 313–20PubMedCrossRefGoogle Scholar
  5. 5.
    Brent DA. Overrepresentation of epileptics in a consecutive series of suicide attempts seen at a children’s hospital, 1978–1983. J Am Acad Child Psychiatry 1986; 25: 242–6PubMedCrossRefGoogle Scholar
  6. 6.
    Brent DA, Crumrine PK, Varma RR, et al. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 1987; 80(6): 909–17PubMedGoogle Scholar
  7. 7.
    Lopez-Gomez M, Ramirez-Bermudez J, Campillo C, et al. Primidone is associated with interictal depression in patients with epilepsy. Epilepsy Behav 2005; 6: 413–6PubMedCrossRefGoogle Scholar
  8. 8.
    Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313(3): 145–51PubMedCrossRefGoogle Scholar
  9. 9.
    Smith DB, Mattson RH, Cramer JA, et al. Results of a nationwide Veterans Administration cooperative study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia 1987; 28 Suppl. 3: S50–8PubMedCrossRefGoogle Scholar
  10. 10.
    Robertson MM, Trimble MR, Townsend HR. Phenomenology of depression in epilepsy. Epilepsia 1987; 28(4): 364–72PubMedCrossRefGoogle Scholar
  11. 11.
    Meador KJ, Loring DW, Allen ME, et al. Comparative cognitive effects of carbamazepine and phenytoin in healthy adults. Neurology 1991; 41: 1537–40PubMedCrossRefGoogle Scholar
  12. 12.
    Schmitz B. Psychiatric syndromes related to antiepileptic drugs. Epilepsia 1999; 40 Suppl. 10: S65–70PubMedCrossRefGoogle Scholar
  13. 13.
    Trimble MR, Schimtz B. Forced normalization and alternative psychoses of epilepsy. Petersfield: Wrightson Biomedical Publishing, 1998Google Scholar
  14. 14.
    Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004; 6(2): 57–75PubMedGoogle Scholar
  15. 15.
    Dodrill CB, Troupin AS. Psychotropic effects of carbamazepine in epilepsy: a double-blind comparison with phenytoin. Neurology 1977; 27(11): 1023–8PubMedCrossRefGoogle Scholar
  16. 16.
    Thompson PJ, Trimble MR. Anticonvulsant drugs and cognitive function. Epilepsia 1982; 23: 531–45PubMedCrossRefGoogle Scholar
  17. 17.
    Andrewes DG, Bullen JG, Tomlinson L, et al. A comparative study of the cognitive effects of phenytoin and carbamazepine in new referrals with epilepsy. Epilepsia 1986; 27(2): 128–34PubMedCrossRefGoogle Scholar
  18. 18.
    Drake Jr ME, Peruzzi WT. Manic state with carbamazepine therapy of seizure. J Natl Med Assoc 1986; 78(11): 1105–7PubMedGoogle Scholar
  19. 19.
    Mula M, Monaco F. Antiepileptic drug-induced mania in patients with epilepsy: what do we know? Epilepsy Behav 2006; 9(2): 265–7PubMedCrossRefGoogle Scholar
  20. 20.
    Lindenmayer JP, Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry 2000; 61(2): 123–8PubMedCrossRefGoogle Scholar
  21. 21.
    Sander JW, Hart YM, Trimble MR, et al. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry 1991; 54(5): 435–9PubMedCrossRefGoogle Scholar
  22. 22.
    Ring HA, Crellin R, Kirker S, et al. Vigabatrin and depression. J Neurol Neurosurg Psychiatry 1993; 56(8): 925–8PubMedCrossRefGoogle Scholar
  23. 23.
    Ferrie CD, Robinson RO, Panaiotopoulos CP. Psychotic and severe behavioural reactions with vigabatrin: a review. Acta Neurol Scand 1996; 93: 1–8PubMedCrossRefGoogle Scholar
  24. 24.
    Levinson DF, Devinsky O. Psychiatric adverse events during vigabatrin therapy. Neurology 1999; 53(7): 1503–11PubMedCrossRefGoogle Scholar
  25. 25.
    Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet 1999; 354(9172): 13–9PubMedCrossRefGoogle Scholar
  26. 26.
    Thomas L, Trimble M, Schmitz B, et al. Vigabatrin and behaviour disorders: a retrospective survey. Epilepsy Res 1996; 25(1): 21–7PubMedCrossRefGoogle Scholar
  27. 27.
    Betts T, Goodwin G, Withers RM, et al. Human safety of lamotrigine. Epilepsia 1991; 32 Suppl. 2: S17–21PubMedCrossRefGoogle Scholar
  28. 28.
    Marson AG, Zadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996; 313(7066): 1169–74PubMedCrossRefGoogle Scholar
  29. 29.
    Beran RG, Gibson RJ. Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia 1998; 39(3): 280–2PubMedCrossRefGoogle Scholar
  30. 30.
    McKee JR, Sunder TR, Vuong A, et al. Adjunctive lamotrigine for refractory epilepsy in adolescents with mental retardation. J Child Neurol 2006; 21(5): 372–9PubMedGoogle Scholar
  31. 31.
    Besag FM. Behavioural effects of the newer antiepileptic drugs: an update. Expert Opin Drug Saf 2004; 3(1): 1–8PubMedCrossRefGoogle Scholar
  32. 32.
    Pellock JM, Pernach JL, Sofia RD. Felbamate. In: Levy R, Mattson R, Meldrum B, et al., editors. Antiepileptic drugs. 5th ed. Baltimore (MD): Lippincott Williams & Wilkins, 2002: 301–18Google Scholar
  33. 33.
    Wolf SM, Shinnar S, Kang H, et al. Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 1995; 36(12): 1203–5PubMedCrossRefGoogle Scholar
  34. 34.
    Lee DO, Steingard RJ, Cesena M, et al. Behavioral side effects of gabapentin in children. Epilepsia 1996; 37(1): 87–90PubMedCrossRefGoogle Scholar
  35. 35.
    Tallian KN, Nahata MC, Lo W, et al. Gabapentin associated with aggressive behavior in pediatric patients with seizures. Epilepsia 1996; 37(5): 501–2PubMedCrossRefGoogle Scholar
  36. 36.
    Sackellares JC, Krauss G, Sommerville KW, et al. Occurrence of psychosis in patients with epilepsy randomized to tiagabine or placebo treatment. Epilepsia 2002; 43(4): 394–8PubMedCrossRefGoogle Scholar
  37. 37.
    Richens A, Chadwick DW, Duncan JS, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res 1995; 21: 37–42PubMedCrossRefGoogle Scholar
  38. 38.
    Uthman BM, Rowan AJ, Ahmann PA, et al. Tiagabine for complex partial seizures. A randomised, add-on, dose-response trial. Arch Neurol 1998; 55: 56–62PubMedCrossRefGoogle Scholar
  39. 39.
    Kälviäinen R, Brodie MJ, Duncan J, et al. A double-blind, placebo-controlled trial of tiagabine given three times daily as add-on therapy for refractory partial seizures. Epilepsy Res 1998; 30: 31–40PubMedCrossRefGoogle Scholar
  40. 40.
    Sachdeo RC, Leroy RF, Krauss GL, et al. Tiagabine therapy for complex partial seizures. A dose-frequency study. Arch Neurol 1997; 54: 595–601PubMedCrossRefGoogle Scholar
  41. 41.
    Ben-Menachem E. International experience with tiagabine addon therapy. Epilepsia 1995; 36 Suppl. 6: S14–21PubMedCrossRefGoogle Scholar
  42. 42.
    Trimble MR, Rusch N, Betts T, et al. Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables. Seizure 2000; 9(4): 249–54PubMedCrossRefGoogle Scholar
  43. 43.
    Aldenkamp AP, De Krom M, De Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003; 44 Suppl. 4: 21–9PubMedCrossRefGoogle Scholar
  44. 44.
    Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999; 52(2): 321–7PubMedCrossRefGoogle Scholar
  45. 45.
    Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996; 25(3): 217–24PubMedCrossRefGoogle Scholar
  46. 46.
    Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind, placebo-controlled trial of topiramate (600mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996; 37(8): 763–8PubMedCrossRefGoogle Scholar
  47. 47.
    Biton V, Montouris GD, Ritter F, et al. A randomized, placebocontrolled study of topiramate in primary generalized tonicclonic seizures. Topiramate YTC Study Group. Neurology 1999; 52(7): 1330–7PubMedCrossRefGoogle Scholar
  48. 48.
    Mula M, Trimble MR, Lhatoo SD, et al. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003; 44(5): 659–63PubMedCrossRefGoogle Scholar
  49. 49.
    Cramer JA, De Rue K, Devinsky O, et al. A systematic review of behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003; 4: 124–32PubMedCrossRefGoogle Scholar
  50. 50.
    Mula M, Trimble MR, Yuen A, et al. Psychiatric adverse events during levetiracetam therapy. Neurology 2003; 61(5): 704–6PubMedCrossRefGoogle Scholar
  51. 51.
    White JR, Walczak TS, Leppik IE, et al. Discontinuation of levetiracetam because of behavioral side effects. A case-control study. Neurology 2003; 61: 1218–21PubMedCrossRefGoogle Scholar
  52. 52.
    Mula M, Trimble MR, Sander JW. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure 2004; 13(1): 55–7PubMedCrossRefGoogle Scholar
  53. 53.
    Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993; 15: 67–73PubMedCrossRefGoogle Scholar
  54. 54.
    Sackellares JC, Ramsay RE, Wilder BJ, et al. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004; 45(6): 610–7PubMedCrossRefGoogle Scholar
  55. 55.
    Faught E, Ayala R, Montouris GG, et al. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001; 57: 1774–9PubMedCrossRefGoogle Scholar
  56. 56.
    Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebocontrolled, multicenter study. J Clin Psychopharmacol 2004; 24(2): 141–9PubMedCrossRefGoogle Scholar
  57. 57.
    Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62(9): 1022–30PubMedCrossRefGoogle Scholar
  58. 58.
    French JA, Kugler AR, Robbins JL, et al. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003; 60(10): 1631–7PubMedCrossRefGoogle Scholar
  59. 59.
    Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, doseresponse study in adults with partial seizures. Epilepsia 2004; 45(1): 20–7PubMedCrossRefGoogle Scholar
  60. 60.
    Beydoun A, Uthman BM, Kugler AR, et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005; 64(3): 475–80PubMedCrossRefGoogle Scholar
  61. 61.
    Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999; 53 (5 Suppl. 2): S53–67PubMedGoogle Scholar
  62. 62.
    Mula M, Cavanna A, Monaco F. Psychopharmacology of topiramate: from epilepsy to bipolar disorder. Neuropsychiatr Dis Treat 2006; 2(4): 475–88PubMedCrossRefGoogle Scholar
  63. 63.
    Perucca E. The clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fund Clin Pharmacol 2001; 15: 405–7CrossRefGoogle Scholar
  64. 64.
    Meldrum BS. Antiepileptic drugs potentiating GABA. Electroencephalogr Clin Neurophysiol 1999; Suppl. 50: 450–7Google Scholar
  65. 65.
    Kuzniecky R, Ho S, Pan J, et al. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 2002; 58(3): 368–72PubMedCrossRefGoogle Scholar
  66. 66.
    Olajide D, Lader M. Depression following withdrawal from long-term benzodiazepine use: a report of four cases. Psychol Med 1984; 14(4): 937–40PubMedCrossRefGoogle Scholar
  67. 67.
    Trimble MR. Biological psychiatry. 2nd ed. Chichester: Wiley, 1996Google Scholar
  68. 68.
    Petty F. GABA and mood disorders: a brief review and hypothesis. J Affect Disord 1995; 34: 275–81PubMedCrossRefGoogle Scholar
  69. 69.
    Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy? Epilepsia 1981; 22(1): 1–10PubMedCrossRefGoogle Scholar
  70. 70.
    Reynolds EH. Neurological aspects of folate and vitamin B12 metabolism. Clin Haematol 1976; 5(3): 661–96PubMedGoogle Scholar
  71. 71.
    Edeh J, Toone BK. Antiepileptic therapy, folate deficiency, and psychiatric morbidity: a general practice survey. Epilepsia 1985; 26(5): 434–40PubMedCrossRefGoogle Scholar
  72. 72.
    Reynolds EH, Carney MW, Toone BK. Methylation and mood. Lancet 1984; 2(8396): 196–8PubMedCrossRefGoogle Scholar
  73. 73.
    Shorvon SD, Carney MW, Chanarin I, et al. The neuropsychiatry of megaloblastic anaemia. BMJ 1980; 281(6247): 1036–8PubMedCrossRefGoogle Scholar
  74. 74.
    Reynolds EH, Travers RD. Serum anticonvulsant concentrations in epileptic patients with mental symptoms. A preliminary report. Br J Psychiatry 1974; 124: 440–5PubMedCrossRefGoogle Scholar
  75. 75.
    Sander JW, Patsalos PN. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res 1992; 13(1): 89–92PubMedCrossRefGoogle Scholar
  76. 76.
    Lishman WA. Epilepsy. In: Lishman WA, editor. Organic psychiatry. 3rd ed. Oxford: Blackwell, 1997: 592–3Google Scholar
  77. 77.
    Quiske A, Helmstaedter C, Lux S, et al. Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res 2000; 39(2): 121–5PubMedCrossRefGoogle Scholar
  78. 78.
    Bremner JD, Narayan M, Anderson ER, et al. Hippocampal volume reduction in major depression. Am J Psychiatry 2000; 157(1): 115–8PubMedGoogle Scholar
  79. 79.
    Frodl T, Meisenzahl EM, Zetzsche T, et al. Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry 2002; 159(7): 1112–8PubMedCrossRefGoogle Scholar
  80. 80.
    Walker MC, White HS, Sander JW. Disease modification in partial epilepsy. Brain 2002; 125 (Pt 9): 1937–50PubMedCrossRefGoogle Scholar
  81. 81.
    French JA, Williamson PD, Thadani VM, et al. Characteristics of medial temporal lobe epilepsy: I. Results of history and physical examination. Ann Neurol 1993; 34: 774–80PubMedCrossRefGoogle Scholar
  82. 82.
    Mula M, Trimble MR, Sander JW. The role of hippocampal sclerosis in topiramate-related depression and cognitive deficits in people with epilepsy. Epilepsia 2003; 44(12): 1573–7PubMedCrossRefGoogle Scholar
  83. 83.
    Mula M, Sander JW, Trimble MR. The role of hippocampal sclerosis in antiepileptic drug-related depression in patients with epilepsy: a study on levetiracetam. Seizure 2006; 15(6): 405–8PubMedCrossRefGoogle Scholar
  84. 84.
    Landolt H. Serial electroencephalographic investigations during psychotic episodes in epileptic patients and during schizophrenic attacks. In: Lorentz de Haas AM, editor. Lectures on epilepsy. Amsterdam: Elsevier, 1958: 91–133Google Scholar
  85. 85.
    Tellenbach H. Epilepsie als Anfallsleiden und als Psychose. Uber alternative Psychosen paranoider Pragung bei ‘forcierter Normalisierung’ (Landolt) des Elektroenzephalogramms epileptischer. Nervenarzt 1965; 36: 190–202PubMedGoogle Scholar
  86. 86.
    Krishnamoorthy ES, Trimble MR. Forced normalization: clinical and therapeutic relevance. Epilepsia 1999; 40 Suppl. 10: S57–64PubMedCrossRefGoogle Scholar
  87. 87.
    Gatzonis SD, Stamboulis E, Siafakas A, et al. Acute psychosis and EEG normalisation after vagus nerve stimulation. J Neurol Neurosurg Psychiatry 2000; 69(2): 278–9PubMedCrossRefGoogle Scholar
  88. 88.
    Wolf P. The clinical syndromes of forced normalization. Folia Psychiatr Neurol Jpn 1984; 38: 187–92Google Scholar
  89. 89.
    Mula M, Trimble MR. The importance of being seizure free: topiramate and psychopathology in epilepsy. Epilepsy Behav 2003; 4(4): 430–4PubMedCrossRefGoogle Scholar
  90. 90.
    Kanner AM, Wuu J, Faught E, et al. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 2003; 4(5): 548–52PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Department of Clinical & Experimental Medicine, Section of NeurologyAmedeo Avogadro UniversityNovaraItaly
  2. 2.Department of Psychiatry, Neurobiology, Pharmacology and BiotechnologiesUniversity of PisaPisaItaly
  3. 3.Department of Clinical & Experimental Epilepsy, Institute of NeurologyUniversity College LondonLondonUK
  4. 4.Epilepsy Institute of the NetherlandsHeemstedeThe Netherlands
  5. 5.Division of NeurologyNovaraItaly

Personalised recommendations